Antidotes and poisoning medical products, part 2 / 2024-2025
Finnish Institute for Health and Welfare · koko Suomi
Perustiedot
- Hankkija
- Finnish Institute for Health and Welfare, Y-tunnus 2229500-6
- Toteutuspaikka
- koko Suomi
- Hankintalaji
- Tavarahankinta
- Menettely
- Avoin menettely, EU-hankinta
- Ilmoituksen tyyppi
- Jälki-ilmoitus
- Sopimusten kokonaisarvo
- 1 € (alv 0 %)
- Erät
- 9 erää
- Pääasiallinen CPV
- 33690000 Muut lääkkeet
- Lisäkoodit: 33600000
- Sopimuskausi
- 17 kuukautta
- Julkaistu
- 10.7.2024
Hankinnan tulos
| Erä | Voittaja | Sopimusarvo | Tarjouksia | Päätös |
|---|---|---|---|---|
| Erä 1: LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15) | Ei voittajaa: Tarjouksia, osallistumishakemuksia tai hankkeita ei saatu | – | 0 | |
| Erä 2: LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15) | Serb | ei ilmoitettu | ei ilmoitettu | |
| Erä 3: LOT 3: Sodiumthiosulfate 25 % / 100 ml (100 ml per vial/ampule, ATC V03AB06) | Dr. Franz Köhler Chemie GmbH | ei ilmoitettu | ei ilmoitettu | |
| Erä 4: LOT 4: Physostigmine 2 mg / 5 ml (5 ml per vial/ampoule, ATC V03AB19) | Dr. Franz Köhler Chemie GmbH | ei ilmoitettu | ei ilmoitettu | |
| Erä 5: LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16) | Ei voittajaa: Tarjouksia, osallistumishakemuksia tai hankkeita ei saatu | – | 0 | |
| Erä 6: LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX) | Viatris Oy, Y-tunnus 2642738-7 | ei ilmoitettu | 1 | |
| Erä 7: LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01) | Ei voittajaa: Tarjouksia, osallistumishakemuksia tai hankkeita ei saatu | – | 0 | |
| Erä 8: LOT 8: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per vial/ampoule/prefilled syringe, ATC L03AA13) | Amgen Ab, Y-tunnus 1090790-9 | ei ilmoitettu | 1 | |
| Erä 9: LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15) | DNE PHARMA AS | ei ilmoitettu | 1 |
Voittajista näytetään nimi ja Y-tunnus. ”Ei ilmoitettu” tarkoittaa, ettei ilmoituksessa ole tätä tietoa erälle tai sopimukselle.
Ilmoituksen teksti
Alkuperäinen teksti Hilmasta, muuttamattomanaThe Scope of the procurement is Antidotes and poisoning medical products (part 2) to the rescEU project. The Scope of procurement is described in more detail in Annex 1.
The procurement is divided in nine (9) lots. Tender may be submitted for one or several lots.
- LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15)
- LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15)
- LOT 3: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06)
- LOT 4: Physostigmine 2 mg/5 ml (5 ml per vial/ampoule, ATC V03AB19)
- LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16)
- LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX)
- LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01)
- LOT 8: Pegfilgrastim 6 mg/0,6 ml (0,6 ml per vial/ampoule/prefilled syringe, ATC L03AA13)
- LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15)
All products are for CBRN poisoning treatment or CBRN antidotes.
The minimum requirements for the articles is described in Annex 1.1.
The contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
The contract period shall enter into force once the contract has been signed by contracting parties and expires when all contractual duties of the contract have been performed.
Estimated quantity for the product in described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the Articles under the Option.
Please note that all times given in the Call for Tenders refer to local time in Finland.
Call for Tenders, Annexes:
Annex 1 Scope of the procurement
Annex 1.1 Minimum requirements
Annex 2 Contract
Annex 3 Security annex
Annex 4 Description of the Handi service
Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022)
Annex 6 Estimated quantity (restricted, TL IV)
Annex 7 Confidentiality commitment
Please note that the numbering of the annexes differs between the Contract and the Call for Tenders.
Lisätiedot
The availability for the Annex 6 is restricted to security classification level IV, TL IV. THL will send the restricted Annex 6 to a representative of the tenderer via encrypted email after THL has received the signed confidentiality commitment (Annex 7). Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the email address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/236/2.02.06/2024 / Antidotes and poisoning medical products, part 2". The message shall contain name of the tenderer and email address to which the restricted Annex 6 is to be sent.
Erien kuvaukset
Erä 1: LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15)
- Parenteral products (intramuscular administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Naloxone
- Strength: 1 mg/ml
- Pharmaceutical form: pre-filled syringe
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 2: LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Naloxone
- Strength: 0,4 mg/ml
- Pharmaceutical form: vial/ampoule
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 3: LOT 3: Sodiumthiosulfate 25 % / 100 ml (100 ml per vial/ampule, ATC V03AB06)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Sodiumthiosulfate 25 % (100 ml per vial/ampule, ATC V03AB06)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Sodiumthiosulfate
- Strength: 25 % / 100 ml
- Pharmaceutical form: vial/ampule
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 4: LOT 4: Physostigmine 2 mg / 5 ml (5 ml per vial/ampoule, ATC V03AB19)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Physostigmine 2 mg / 5 ml (5 ml per vial/ampoule, ATC V03AB19)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Physostigmine
- Strength: 2 mg / 5 ml
- Pharmaceutical form: vial/ampoule
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 5: LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Ethanol
- Strength: 95 – 96 % / 20 ml
- Pharmaceutical form: vial/ampoule
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 6: LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Silibinin (350 mg powder for i.v. / vial, ATC V03AX)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Silibinin
- Pharmaceutical form: powder for i.v. / vial
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 7: LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01)
- Parenteral products (intravenous administration) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Atropine sulphate
- Strength: 10 mg/ml
- Pharmaceutical form: vial/ampoule
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 8: LOT 8: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per vial/ampoule/prefilled syringe, ATC L03AA13)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per vial/ampoule/prefilled syringe, ATC L03AA13)
- Parenteral products (sub-cutaneous) for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Pegfilgrastim
- Strength: 6 mg / 0,6 ml
- Pharmaceutical form: vial/ampoule/prefilled syringe
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 9: LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15)
The subject of the procurement is article in accordance with the following requirements:
- The subject of tender: Naloxone / single dose container (no further device assembly is required, ATC V03AB15)
- Solutions for nasal use for CBRN poisoning treatment or CBRN antidotes
- Active pharmaceutical ingredient: Naloxone
- Pharmaceutical form: single dose container (no further device assembly is required)
The minimum requirements of the article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erät
| Erä | Nimi | Ammattiala | Arvioitu arvo | CPV |
|---|---|---|---|---|
| 1 | LOT 1: Naloxone 1 mg/ml (2 ml per pre-filled syringe, ATC V03AB15) | – | – | 33690000, 33600000 |
| 2 | LOT 2: Naloxone 0,4 mg/ml (1 ml per vial/ampoule, ATC V03AB15) | – | – | 33690000, 33600000 |
| 3 | LOT 3: Sodiumthiosulfate 25 % / 100 ml (100 ml per vial/ampule, ATC V03AB06) | – | – | 33690000, 33600000 |
| 4 | LOT 4: Physostigmine 2 mg / 5 ml (5 ml per vial/ampoule, ATC V03AB19) | – | – | 33690000, 33600000 |
| 5 | LOT 5: Ethanol 95 – 96 % / 20 ml (20 ml per vial/ampoule, ATC V03AB16) | – | – | 33690000, 33600000 |
| 6 | LOT 6: Silibinin (350 mg powder for i.v. / vial, ATC V03AX) | – | – | 33690000, 33600000 |
| 7 | LOT 7: Atropine sulphate 10 mg/ml (10 ml per vial/ampoule, ATC A03BA01) | – | – | 33690000, 33600000 |
| 8 | LOT 8: Pegfilgrastim 6 mg / 0,6 ml (0,6 ml per vial/ampoule/prefilled syringe, ATC L03AA13) | – | – | 33690000, 33600000 |
| 9 | LOT 9: Naloxone / single dose container (no further device assembly is required, ATC V03AB15) | – | – | 33690000, 33600000 |
Hankinnan vaiheet
-
–Hankintailmoitus
Aiempi versio. Sen tiedot eivät ole Urakkahaussa.
-
Julkaisijan virheen korjaaminen.
-
Jälki-ilmoitustämä ilmoitus
Voittajat: Serb, Dr. Franz Köhler Chemie GmbH, Viatris Oy ja 2 muuta.